Schedule at a Glance - EDT

• Kenneth D. Burman, MD – Lewis E. Braverman Distinguished Lectureship
• Van Meter Award Lecturer to be announced during the plenary session

•Ashish Chintakuntlawar, MD, Moderator

Clinical Perspectives on Molecular Testing and Personalized Thyroid Cancer Therapy
•Mimi Hu, MD

Pathology Perspectives on Molecular Testing and Personalized Thyroid Cancer Therapy
•Thomas Giordano, MD, PhD

• Leonidas Duntas, MD, Moderator

Basic/Translational Update of Autoimmune Thyroiditis
• Francesca Coscia, PhD

Clinical Update in Thyroid Autoimmunity
• Giuseppe Barbesino, MD

• Whitney Goldner, MD and Andy Bauer, MD Co-Chairs

Perspectives From a Pediatric and Adult Endocrinologist: Advances and Gaps in Care Across the Age Spectrum
• Steve Waguespack, MD

Challenges and Considerations in the Care of Adolescent and Young Adult (AYA) with Thyroid Cancer
• Melanie Goldfarb, MD

Practical Considerations on Managing Thyroid Cancer in Older Adults
• Maria Papaleontiou, MD

• Rossella Elisei, MD and Peter Kopp, MD, Co-chairs

The Spectrum of Thyroid Function Abnormalities in COVID-19 Patients
• Laura Fugazzola, MD

Treatment of SARS with L-T3
• David Ingbar, MD

Analysis of Risk, Disparity and Outcomes in COVID-19 Patients with Thyroid Cancer
• Melissa Lechner, MD

• Tracy Tylee, MD, Moderator

Long Term ATD – Is it a Better Way?
• Fereidoun Azizi, MD

Shifts in Treatment Preferences – Where we were, Where we are, and Where we’re going
• Doug Ross, MD

• John Morris, MD and Sissy Jhiang, PhD Co-Chairs
• Gregory A. Brent, MD, “NIS- The basis of 80 years of radioiodine therapy in benign and malignant disease”
• Nancy Carrasco, MD, “NIS – The journey since its cloning 25 years ago”

•Cari Kitahara, PhD, Moderator

Impact of Overdiagnosis on International Patterns in Thyroid Cancer Incidence and Mortality
•Salvatore Vaccarella, PhD

Is There Evidence of True Increase in Incidence?
•Susan Jordan, PhD

•Kris Poppe, MD, Moderator

Issues in the Pregnant or Lactating Patient with Thyroid Cancer
•Angela Leung, MD

Preconception Counselling and Care for Pregnant Women with Autoimmune Thyroid Disease
•Kristien Boelaert, MD

• Anne Cappola, MD and Laszlo Hegedus, MD, DMSc Co-Chairs

How to Use LT3 + LT4 today
• Jacqueline Jonklaas, MD, PhD

Clinical Trials Underway
• Colin Dayan, MA,FRCP,PhD

New Formulations of Liothyronine
• Antonio Bianco, MD, PhD

• Monica Dentice, PhD, Chair

Loss-of-Function Mutations of DIO1
• Alexandra Dumitrescu, MD, PhD

Loss-of-Function Mutations of DIO2
• Jose Moreno, MD, PhD

Syndromes of DIO3 Reactivation
• Dominico Salvatore, MD

•Steven Sherman, MD and Lori Wirth, MD Co-Chairs

Targeted Therapies in DTC and MTC: Where Have we Started and What Have we Achieved
•Manisha Shah, MD

Update in Management of Anaplastic Thyroid Cancer: 2021 ATA Guidelines
•Keith Bible, MD

Current and Upcoming Clinical Trials in Thyroid Cancer
•Maria Cabanillas, MD

• Cord Sturgeon, MD, MS, FACS, Moderator

Consideration for Surgery vs RAI Referral
• Brian Kim, MD

Preop Management of the Thyrotoxic Patient, Operative Considerations and Challenges, and Postop Challenges
• Susan Pitt, MD

4:00 – 5:00 pm – Highlighted Poster Presentations

• M. Regina Castro, MD and Ernest Asamoah, MD, Co-Chairs
• Emad Kandil, MD, “Disparities in Surgical Management of Thyroid Disease”
• Julie Ann Sosa, MD, “Disparities in Differentiated Thyroid Cancer Care”
• Donald S. A. McLeod, MBBS, MPH, PhD, “Disparities in Management of Graves’ Disease”

• Andrew Gianoukakis, MD, Moderator

Thyroid Storm: Myths and Facts
• Takashi Akamizu, MD

Thyroid lymphoma: a diagnosis to consider in the rapidly enlarging thyroid mass
• Anu Sharma, MD

• Pilar Santisteban, PhD and Christine Spitzweig, MD Co-Chairs

Pathophysiology of Radioiodine-Refractory DTC
• James Fagin, MD

Update on Redifferentiation Trials in Radioiodine-Refractory DTC
• Sophie Leboulleux, MD

New Insights into Regulation of NIS Expression and Function
• Chris McCabe, PhD

• Bhavana Konda, MD, MPH and Mabel Ryder, MD, Co-Chairs

Management of Endocrine Side Effects of Immunotherapy
• Anupam Kotwal, MD

Pembrolizumab and Lenvatinib – A Powerful Duo in Differentiated and Undifferentiated Thyroid Cancer
• Bryan Haugen, MD

Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy for the Development of Rational Combination Therapies
• Padmanee Sharma, MD, PhD